Track topics on Twitter Track topics that are important to you
MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) Monday announced it has stopped the clinical development program of MOR106 in atopic dermatitis, due to low probability to meet main goal of study.The co...
Original Article: MorphoSys Stops Clinical Development MOR106 In Atopic DermatitisNEXT ARTICLE
Eczema is a common itchy skin disease characterized by reddening and vesicle formation, which may lead to weeping and crusting. It is endogenous, or constitutional. There are five main types; atopic, seborrhoeic, discoid, gravitational or varicose. ...